DB16429InvestigationalVaccines
Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein . It is... It is being investigated in the clinical trial NCT04546841 (Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC)) and aims to induce broad T-cell immunity.
- Also known as
- Multi-peptide vaccination · Multipeptide cocktail
- Code names
- CoVac-1
What you can answer from here — as of May 21, 2026
Which companies are running trials of CoVac-1, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account